Beta Bionics’ iLet bionic pancreas system significantly increased the percentage of time that adults with Type 1 diabetes spent with glucose levels between 70–180 mg/dl when compared to usual care therapy, according to a new study. The study’s results also suggest that the iLet, using either the Senseonics (NYSE:SENS) Eversense continuous glucose monitoring system (CGM) […]
DexCom Inc.
Dexcom, Companion Medical will share glucose, insulin data
Dexcom (NSDQ:DXCM) and Companion Medical have announced a collaboration to enable a direct exchange of continuous glucose monitoring (CGM) data from Dexcom with insulin data from InPen into both companies’ software applications. Companion made a partnership deal with Glooko this week to integrate data from its InPen smart insulin injection pen into Glooko’s diabetes data […]
Dexcom shares steady after posting Street-beating Q1 earnings
Shares in Dexcom (NSDQ:DXCM) are steady in after-hours trading today after the diabetes-focused device maker posted first quarter 2019 earnings that topped loss-per-share and sales expectations. The San Diego-based company posted losses of $26.9 million, or 30¢ per share, on sales of $280.5 million for the three months ended March 31, seeing losses grow 11.2% while […]
Glooko, Novo Nordisk team up for connected insulin pens
Glooko announced this month that it’s teaming up to connect Novo Nordisk‘s (NYSE:NVO) insulin pens with the company’s diasend diabetes management solution. Novo Nordisk plans to launch its connected insulin pens, the NovoPen 6 and NovoPen Echo Plus, in early 2019. Any provider using diasend and any person using the diasend mobile app will be able […]
Dexcom wins Health Canada nod for G6 CGM
Dexcom (NSDQ:DXCM) said last week that it won Health Canada approval for its G6 continuous glucose monitoring system for people with diabetes ages two and up. The company plans to kick off the G6 commercial launch later this year. Dexcom’s G6 device includes a transmitter, a sensor with an auto-applicator and a touchscreen receiver. The […]
Dexcom beats The Street with Q4, FY18 results
Dexcom (NSDQ:DXCM) topped expectations on Wall Street this week with its fourth quarter and full-year financial results. The San Diego, Calif.-based company posted a net loss of -$179.7 million, or -$2.03 per share, on sales of $338 million for the 3 months ended Dec. 31, for sales growth of 52.9% compared with the same period last […]
Dexcom Q4 prelims top consensus | Wall Street Beat
Dexcom (NSDQ:DXCM) topped estimates on Wall Street today with preliminary results for its fourth-quarter financial results. The San Diego, Calif.-based company said it expects to report $331 million in sales for the quarter ended Dec. 31 – up at least 50% from the same period last year. For the full year of 2018, Dexcom is slated […]
Dexcom completes $850m debt offering
Dexcom (NSDQ:DXCM) said that it completed the sale of $850 million of 0.75% convertible senior notes due 2023. The San Diego, Calif.-based company expects to reel in roughly $836 million in net proceeds from the offering. Dexcom used $35.1 million of the offering’s proceeds to pay the cost of the convertible note hedge transactions as described […]
Diabeloop wins CE Mark for hybrid closed-loop diabetes management system
Diabeloop won CE Mark clearance in the European Union this month for its hybrid closed-loop diabetes management system, DBLG1. The Paris-based company hopes to launch its “artificial pancreas” system for adults with Type I diabetes in Europe by the second quarter in 2019. Diabeloop’s system connects Dexcom‘s (NSDQ:DXCM) G6 continuous glucose monitor, Kaleido’s patch insulin […]
Dexcom prices $750m debt offering
Dexcom (NSDQ:DXCM) today priced its $750 million offering of convertible senior notes due 2023 which is slated to be offered to qualified institutional buyers. The San Diego, Calif.-based company said that it will also offer a 13-day option to buy up to an additional $100 million aggregate principal amount of notes to purchasers in the offering. […]
